List of aminorex analogues explained

This is a list of aminorex analogues. Aminorex itself is a stimulant drug with a 5-phenyl-2-amino-oxazoline structure. It was developed in the 1960s as an anorectic,^{[1] [2] [3]} but withdrawn from sale after it was discovered that extended use produced pulmonary hypertension, often followed by heart failure, which resulted in a number of deaths.^[4] A designer drug analogue 4-methylaminorex appeared on the illicit market in the late 1980s but did not attract significant popularity due to its steep dose-response curve and tendency to produce seizures.^{[5] [6] [7] [8]} Pemoline, the 4-keto derivative of aminorex, had been discovered several years earlier,^[9] and derivatives of this type appeared to be effective stimulants with comparatively low toxicity.^{[10] [11]} Pemoline was sold for around 25 years as a therapy for ADHD and relief of fatigue, before being withdrawn from the market in 2005 because of rare but serious cases of liver failure.^{[12] [13] [14] [15]} More recently in around 2014 another derivative 4,4'-dimethylaminorex started to be sold illicitly, but again swiftly lost popularity due to a spate of fatal overdose cases.^{[16] [17] [18]} A number of related compounds are known, and new derivatives have continued to appear on the designer drug market.^{[19] [20] [21] [22] [23] [24]}

List of substituted aminorex derivatives

Structure	Common name	Chemical name	CAS number
	Aminorex	5-phenyl-4,5-dihydro-1,3-oxazol-2-amine	2207-50-3
	Rexamino	4-phenyl-4,5-dihydro-1,3-oxazol-2-amine	52883-35-9
	4'-Fluoroaminorex (4'-FAR)	5-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine	2967-77-3
	Clominorex	5-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-2-amine	3876-10-6
	Fluminorex	5-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazol-2-amine	720-76-3
	Methylenedioxyaminorex	5-(3,4-methylenedioxyphenyl)-4,5-dihydro-1,3-oxazol-2-amine	3865-98-3
	2C-B-aminorex (2C-B-AR)	5-(2,5-dimethoxy-4-bromophenyl)-4,5-dihydro-1,3-oxazol-2-amine
	N,N-Dimethylaminorex (N,N-DMAR)	N,N-dimethyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine	32968-41-5
	Pemoline	2-amino-5-phenyl-1,3-oxazol-4(5H)-one	2152-34-3
	Thozalinone	2-(dimethylamino)-5-phenyl-1,3-oxazol-4(5H)-one	655-05-0
	Fenozolone	2-ethylamino-5-phenyl-1,3-oxazol-4-one	15302-16-6
	Cyclazodone	2-(cyclopropylamino)-5-phenyl-1,3-oxazol-4-one	14461-91-7
	N-Methylcyclazodone	2-(cyclopropyl(methyl)amino)-5-phenyl-1,3-oxazol-4-one	14461-92-8
	Ephedroxane [25]	(4S,5R)-3,4-dimethyl-5-phenyl-1,3-oxazolidin-2-one	16251-46-0
	3-Methylaminorex	3-methyl-5-phenyl-2-oxazolidinimine	75343-73-6
	4-Methylaminorex (4-MAR)	4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine	3568-94-3
	4-Ethylaminorex (4-EAR)	4-ethyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine	1364933-63-0
	4-Isopropylaminorex	4-isopropyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine
	4-Isobutylaminorex	4-(2-methylpropyl)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine
	4-tert-butylaminorex	4-(1,1-dimethylethyl)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine
	4,N-Dimethylaminorex (4,N-DMAR)	4,5-dihydro-N,4-dimethyl-5-phenyl-2-oxazolamine	2207-49-0
	3,4-Dimethylaminorex (3,4-DMAR)	3,4-dimethyl-5-phenyl-2-oxazolidinimine	82485-31-2
	4,4'-Dimethylaminorex (4,4'-DMAR)	4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine	1445569-01-6
	2'-Fluoro-4-methylaminorex (2F-MAR)	4-methyl-5-(2-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine
	3'-Fluoro-4-methylaminorex (3F-MAR)	4-methyl-5-(3-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine
	4'-Fluoro-4-methylaminorex (4F-MAR)	4-methyl-5-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine	1364933-64-1
	4'-Chloro-4-methylaminorex (4C-MAR)	4-methyl-5-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-2-amine
	4'-Bromo-4-methylaminorex (4B-MAR)	4-methyl-5-(4-bromophenyl)-4,5-dihydro-1,3-oxazol-2-amine
	4'-Methoxy-4-methylaminorex (4'-MeO-4-MAR)	4-methyl-5-(4-methoxyphenyl)-4,5-dihydro-1,3-oxazol-2-amine	1445570-65-9
	3',4',5'-Trimethoxy-4-methylaminorex (TM-4-MAR)	4-methyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1,3-oxazol-2-amine	1445571-92-5
	3',4'-Methylenedioxy-4-methylaminorex (MDMAR)	4-methyl-5-(3,4-methylenedioyphenyl)-4,5-dihydro-1,3-oxazol-2-amine	1445573-16-9

See also

• Berefrine
• RO5166017
• List of methylphenidate analogues
• Substituted benzofuran
• Substituted cathinone
• Substituted phenylmorpholine

Notes and References

1. https://patents.google.com/patent/US3115494 Meschino JA, Poos GI. 2-amino-5,6-dihydro-4H-1,3-oxazines and a process for their preparation. US Patent 3115494, 1961
2. https://patents.google.com/patent/US3161650 Poos GI. 2-amino-5-aryloxazoline products. US Patent 3161650, 1962
3. Poos GI, Carson JR, Rosenau JD, Roszkowski AP, Kelley NM, Mcgowin J . 2-Amino-5-aryl-2-oxazolines. Potent New Anorectic Agents . Journal of Medicinal Chemistry . 6 . 3 . 266–272 . May 1963 . 14185981 . 10.1021/jm00339a011 .
4. Gurtner HP . Aminorex and pulmonary hypertension. A review . Cor et Vasa . 1985 . 27 . 2–3 . 160–171 . 3928246 .
5. Davis FT, Brewster ME . A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine . Journal of Forensic Sciences . 33 . 2 . 549–553 . March 1988 . 10.1520/JFS11971J . 3373171 .
6. Bunker CF, Johnson M, Gibb JW, Bush LG, Hanson GR . Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse . European Journal of Pharmacology . 180 . 1 . 103–111 . May 1990 . 10.1016/0014-2999(90)90597-y . 1973111 .
7. Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, Traill TA . Recreational use of aminorex and pulmonary hypertension . Chest . 118 . 5 . 1496–1497 . November 2000 . 10.1378/chest.118.5.1496 . 11083709 .
8. Meririnne E, Kajos M, Kankaanpää A, Koistinen M, Kiianmaa K, Seppälä T . Rewarding properties of the stereoisomers of 4-methylaminorex: involvement of the dopamine system . Pharmacology, Biochemistry, and Behavior . 81 . 4 . 715–724 . August 2005 . 10.1016/j.pbb.2005.04.020 . 15982727 . 21142560 .
9. https://patents.google.com/patent/US2892753 Schmidt L, Scheffler H. Central nervous system stimulant. US Patent 2892753, 1957
10. Web site: Hardy RA, Howell CF, Quinones NQ. Method of producing central nervous system stimulation and anorexia. US Patent 3313688, 1964 . 2019-06-14 . 2021-05-31 . https://web.archive.org/web/20210531152352/https://patents.google.com/patent/US3313688 . live .
11. Web site: Guidicelli DP, Najer H. 5-phenyl-2-cyclopropylamino-4-oxazolinone, and process for making the same. US Patent 3609159, 1967 . 2019-06-14 . 2021-05-31 . https://web.archive.org/web/20210531152337/https://patents.google.com/patent/US3609159 . live .
12. Marotta PJ, Roberts EA . Pemoline hepatotoxicity in children . The Journal of Pediatrics . 132 . 5 . 894–897 . May 1998 . 10.1016/s0022-3476(98)70329-4 . 9602211 .
13. Safer DJ, Zito JM, Gardner JE . Pemoline hepatotoxicity and postmarketing surveillance . Journal of the American Academy of Child and Adolescent Psychiatry . 40 . 6 . 622–629 . June 2001 . 10.1097/00004583-200106000-00006 . 11392339 .
14. Etwel FA, Rieder MJ, Bend JR, Koren G . A surveillance method for the early identification of idiosyncratic adverse drug reactions . Drug Safety . 31 . 2 . 169–180 . 2008 . 18217792 . 10.2165/00002018-200831020-00006 . 19964105 .
15. Shader RI . Risk Evaluation and Mitigation Strategies (REMS), Pemoline, and What Is a Signal? . Clinical Therapeutics . 39 . 4 . 665–669 . April 2017 . 28366595 . 10.1016/j.clinthera.2017.03.008 . free .
16. Brandt SD, Baumann MH, Partilla JS, Kavanagh PV, Power JD, Talbot B, Twamley B, Mahony O, O'Brien J, Elliott SP, Archer RP, Patrick J, Singh K, Dempster NM, Cosbey SH . 6 . Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4'-DMAR, or 'Serotoni') . Drug Testing and Analysis . 2014 . 6 . 7–8 . 684–695 . 10.1002/dta.1668 . 24841869 . 4128571 .
17. Coppola M, Mondola R . 4,4'-DMAR: chemistry, pharmacology and toxicology of a new synthetic stimulant of abuse . Basic & Clinical Pharmacology & Toxicology . 117 . 1 . 26–30 . July 2015 . 10.1111/bcpt.12399 . 25819702 . free .
18. Maier J, Mayer FP, Luethi D, Holy M, Jäntsch K, Reither H, Hirtler L, Hoener MC, Liechti ME, Pifl C, Brandt SD, Sitte HH . 6 . The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters . Neuropharmacology . 138 . 282–291 . August 2018 . 10.1016/j.neuropharm.2018.06.018 . 29908239 . 49274224 . free .
19. Russell BR, Beresford RA, Schmierer DM, McNaughton N, Clark CR . Stimulus properties of some analogues of 4-methylaminorex . Pharmacology, Biochemistry, and Behavior . 1995 . 51 . 2–3 . 375–378 . 10.1016/0091-3057(94)00407-a . 7667356 . 28367828 .
20. Zheng Y, Russell B, Schmierer D, Laverty R . The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice . The Journal of Pharmacy and Pharmacology . 49 . 1 . 89–96 . January 1997 . 10.1111/j.2042-7158.1997.tb06758.x . 9120777 . 20224300 . free .
21. McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Mahony O, Brandt SD, Patrick J, Archer RP, Partilla JS, Baumann MH . 6 . Synthesis, characterization, and monoamine transporter activity of the new psychoactive substance 3',4'-methylenedioxy-4-methylaminorex (MDMAR) . Drug Testing and Analysis . 7 . 7 . 555–564 . July 2015 . 10.1002/dta.1732 . 25331619 . 5331736 .
22. Maier J, Mayer FP, Brandt SD, Sitte HH . DARK Classics in Chemical Neuroscience: Aminorex Analogues . ACS Chemical Neuroscience . 9 . 10 . 2484–2502 . October 2018 . 10.1021/acschemneuro.8b00415 . 30269490 . 6287711 .
23. Fabregat-Safont D, Carbón X, Ventura M, Fornís I, Hernández F, Ibáñez M . Characterization of a recently detected halogenated aminorex derivative: para-fluoro-4-methylaminorex (4'F-4-MAR) . Scientific Reports . 9 . 1 . 8314 . June 2019 . 10.1038/s41598-019-44830-y . 31165778 . 6549166 . 2019NatSR...9.8314F .
24. Rickli A, Kolaczynska K, Hoener MC, Liechti ME . Pharmacological characterization of the aminorex analogs 4-MAR, 4,4'-DMAR, and 3,4-DMAR . Neurotoxicology . 72 . 95–100 . May 2019 . 10.1016/j.neuro.2019.02.011 . 30776375 . 2019NeuTx..72...95R . 73474963 .
25. Hikino H, Ogata K, Kasahara Y, Konno C . Pharmacology of ephedroxanes . Journal of Ethnopharmacology . 13 . 2 . 175–191 . May 1985 . 10.1016/0378-8741(85)90005-4 . 4021515 .